PM
BLCM

Prosight Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Prosight Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,605
Closed -$696K – 35
2018
Q1 		$696K Sell
10,605
-19,530
-65% -$1.47M 0.44% 30
2017
Q4 		$2.53M Buy
+30,135
New +$2.96M 1.86% 21

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosight Management's BLCM Position: Q2 2018 in Review

Prosight Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 10,605 shares — an estimated $696K sold.

Prosight Management first reported a position in BLCM in Q4 2017 and held it in 2 quarters. The position peaked at $2.53M in Q4 2017. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • Prosight Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Prosight Management sold 10,605 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $696K.
  • Prosight Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Prosight Management's Bellicum Pharmaceuticals, Inc. position peaked at $2.53M in Q4 2017.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Prosight Management's 13F filing for Q2 2018, filed 14 Aug 2018.